| Paige Marie Trammell, DPT, OCS, MTC | |
|
831 1st St N Ste B, Alabaster, AL 35007-8944 | |
| (205) 358-9138 | |
| (205) 358-9139 |
| Full Name | Paige Marie Trammell |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 18 Years |
| Location | 831 1st St N Ste B, Alabaster, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255530036 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT 22665 (Florida) | Secondary |
| 225100000X | Physical Therapist | PTH6226 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Encore Rehabilitation, Inc | 3577462126 | 150 |
News Archive
The John Theurer Cancer Center at Hackensack University Medical Center's Cutaneous Malignancies Program has partnered with The Promise Foundation to host a skin cancer screening event on Thursday, June 2 from 10am -5pm. This program will feature educational information on skin cancer prevention and offer free skin cancer screenings by appointment only for the community.
Interleukin Genetics, Inc. announced today that the Corporate Compliance Staff of the NYSE Amex LLC has granted the Company an extension to meet the Exchange's continued listing standards and become compliant. The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.
In a study of patients with anal cancer, living in low median household income areas was linked with an increased risk of early death. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that socioeconomic inequalities may affect cancer outcomes, especially for highly treatable and curable tumors such as anal cancer.
INVISTA and Eucodis Bioscience, an Austrian biotechnology company with strong expertise in enzyme engineering and industrial enzyme development, announce a collaboration for the screening and engineering of enzymes to further develop bio-derived processes for the production of industrial chemicals.
EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.
› Verified 5 days ago
| Provider Name | Encore Rehabilitation, Inc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1003819608 PECOS PAC ID: 3577462126 Enrollment ID: O20051103001194 |
News Archive
The John Theurer Cancer Center at Hackensack University Medical Center's Cutaneous Malignancies Program has partnered with The Promise Foundation to host a skin cancer screening event on Thursday, June 2 from 10am -5pm. This program will feature educational information on skin cancer prevention and offer free skin cancer screenings by appointment only for the community.
Interleukin Genetics, Inc. announced today that the Corporate Compliance Staff of the NYSE Amex LLC has granted the Company an extension to meet the Exchange's continued listing standards and become compliant. The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.
In a study of patients with anal cancer, living in low median household income areas was linked with an increased risk of early death. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that socioeconomic inequalities may affect cancer outcomes, especially for highly treatable and curable tumors such as anal cancer.
INVISTA and Eucodis Bioscience, an Austrian biotechnology company with strong expertise in enzyme engineering and industrial enzyme development, announce a collaboration for the screening and engineering of enzymes to further develop bio-derived processes for the production of industrial chemicals.
EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.
› Verified 5 days ago
| Provider Name | Drayer Physical Therapy-alabama, Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1023440583 PECOS PAC ID: 5395970560 Enrollment ID: O20150417000513 |
News Archive
The John Theurer Cancer Center at Hackensack University Medical Center's Cutaneous Malignancies Program has partnered with The Promise Foundation to host a skin cancer screening event on Thursday, June 2 from 10am -5pm. This program will feature educational information on skin cancer prevention and offer free skin cancer screenings by appointment only for the community.
Interleukin Genetics, Inc. announced today that the Corporate Compliance Staff of the NYSE Amex LLC has granted the Company an extension to meet the Exchange's continued listing standards and become compliant. The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.
In a study of patients with anal cancer, living in low median household income areas was linked with an increased risk of early death. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that socioeconomic inequalities may affect cancer outcomes, especially for highly treatable and curable tumors such as anal cancer.
INVISTA and Eucodis Bioscience, an Austrian biotechnology company with strong expertise in enzyme engineering and industrial enzyme development, announce a collaboration for the screening and engineering of enzymes to further develop bio-derived processes for the production of industrial chemicals.
EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.
› Verified 5 days ago
| Provider Name | Ati Holdings Of Alabama Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1063952646 PECOS PAC ID: 2769756436 Enrollment ID: O20170919001462 |
News Archive
The John Theurer Cancer Center at Hackensack University Medical Center's Cutaneous Malignancies Program has partnered with The Promise Foundation to host a skin cancer screening event on Thursday, June 2 from 10am -5pm. This program will feature educational information on skin cancer prevention and offer free skin cancer screenings by appointment only for the community.
Interleukin Genetics, Inc. announced today that the Corporate Compliance Staff of the NYSE Amex LLC has granted the Company an extension to meet the Exchange's continued listing standards and become compliant. The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.
In a study of patients with anal cancer, living in low median household income areas was linked with an increased risk of early death. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that socioeconomic inequalities may affect cancer outcomes, especially for highly treatable and curable tumors such as anal cancer.
INVISTA and Eucodis Bioscience, an Austrian biotechnology company with strong expertise in enzyme engineering and industrial enzyme development, announce a collaboration for the screening and engineering of enzymes to further develop bio-derived processes for the production of industrial chemicals.
EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paige Marie Trammell, DPT, OCS, MTC 2416 Highway 45 N, Suite 202, Columbus, MS 39705-1320 Ph: (662) 327-6705 | Paige Marie Trammell, DPT, OCS, MTC 831 1st St N Ste B, Alabaster, AL 35007-8944 Ph: (205) 358-9138 |
News Archive
The John Theurer Cancer Center at Hackensack University Medical Center's Cutaneous Malignancies Program has partnered with The Promise Foundation to host a skin cancer screening event on Thursday, June 2 from 10am -5pm. This program will feature educational information on skin cancer prevention and offer free skin cancer screenings by appointment only for the community.
Interleukin Genetics, Inc. announced today that the Corporate Compliance Staff of the NYSE Amex LLC has granted the Company an extension to meet the Exchange's continued listing standards and become compliant. The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.
In a study of patients with anal cancer, living in low median household income areas was linked with an increased risk of early death. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that socioeconomic inequalities may affect cancer outcomes, especially for highly treatable and curable tumors such as anal cancer.
INVISTA and Eucodis Bioscience, an Austrian biotechnology company with strong expertise in enzyme engineering and industrial enzyme development, announce a collaboration for the screening and engineering of enzymes to further develop bio-derived processes for the production of industrial chemicals.
EntreMed, Inc. today announced the initiation of a multi-center Phase 2 study with its lead oncology product candidate, ENMD-2076, in patients with platinum resistant ovarian cancer. The study will be conducted at up to six sites in the United States and Canada. In addition, EntreMed received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct the Phase 2 clinical trial in ovarian cancer patients.
› Verified 5 days ago
Lisa Anne Vogel, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 750 Colonial Promenade Pkwy, Suite 4400, Alabaster, AL 35007 Phone: 205-358-1040 Fax: 205-358-1041 | |
Patrick Ogg, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Gilbert Dr, Alabaster, AL 35007 Phone: 205-259-3991 Fax: 205-621-2212 | |
Madeline Grace Lee, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 831 1st St N Ste B, Alabaster, AL 35007 Phone: 205-358-9138 Fax: 205-803-6642 | |
Shelby Grace Troyer, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 831 1st St N, Suite B, Alabaster, AL 35007 Phone: 205-358-9138 Fax: 205-358-9139 | |
Morgan Gibson, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 750 Colonial Promenade Pkwy Ste 4400, Alabaster, AL 35007 Phone: 205-358-1040 Fax: 205-358-1041 | |
Encore Rehabilitation, Inc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 831 1st St N Ste B, Alabaster, AL 35007 Phone: 205-605-9005 Fax: 205-624-8092 |